Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non –Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
In conclusion, tropifexor was well tolerated, had a pharmacokinetic profile suitable for on ce‐daily dosing and showed dose‐dependent target engagement without altering plasma lipids in healthy volunteers.
Source: Clinical Pharmacology in Drug Development - Category: Drugs & Pharmacology Authors: Michael K. Badman,
Jin Chen,
Sachin Desai,
Soniya Vaidya,
Srikanth Neelakantham,
Jie Zhang,
Lu Gan,
Kate Danis,
Bryan Laffitte,
Lloyd B. Klickstein Tags: Original Manuscript Source Type: research
More News: Bile | Drugs & Pharmacology | Eating Disorders & Weight Management | Liver | Liver Disease | Obesity | Study | Urology & Nephrology